The executive vice president of oncology therapeutics at Gilead Sciences will leave the company to pursue another opportunity, the company announced this week.
Alessandro Riva, MD, joins a long list of leadership departures from Gilead. The company also saw its CEO John Milligan, Chairman John Martin, R&D chief Norbert Bischofberger and CMO Andrew Cheng exit the company.
Dr. Riva is shifting to lead a new biotech spinoff from India's Glenmark, which will be based in the U.S. The spinoff will focus on oncology and T-cell therapies, according to EndPoints News.
Dr. Riva joined Gilead in January 2017 and will remain with the company until the end of March.